EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review.

Genes Cancer · 2017 · PMC5511892 · PMID 28740577

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In NSCLC for example, high levels of pAKT predicted better response to TKI (gefinitinib) therapy and significantly longer time to progression in one study [ 63 ], and in another study, pAKT and pSTAT3 both showed a trend towards association with longer time to progression on gefitinib [ 64 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.